3.財務諸表及び主な注記
(1)貸借対照表
| | (単位:千円) |
| 前事業年度 (2023年12月31日) | 当事業年度 (2024年12月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 1,325,554 | 2,063,280 |
売掛金 | 83,193 | 51,063 |
棚卸資産 | 64,107 | 46,171 |
前渡金 | 86,797 | 101,992 |
前払費用 | 43,845 | 46,656 |
未収消費税等 | 25,046 | 24,425 |
その他 | 849 | 4,081 |
流動資産合計 | 1,629,396 | 2,337,672 |
固定資産 | | |
有形固定資産 | | |
機械及び装置 | 233,509 | 230,491 |
減価償却累計額 | △232,343 | △230,491 |
機械及び装置(純額) | 1,166 | 0 |
工具、器具及び備品 | 85,451 | 82,364 |
減価償却累計額 | △85,451 | △82,364 |
工具、器具及び備品(純額) | 0 | 0 |
有形固定資産合計 | 1,166 | 0 |
投資その他の資産 | | |
敷金及び保証金 | 112,811 | 112,809 |
長期前払費用 | 8,081 | 18,375 |
その他 | 0 | 0 |
投資その他の資産合計 | 120,892 | 131,184 |
固定資産合計 | 122,058 | 131,185 |
資産合計 | 1,751,454 | 2,468,857 |
| | (単位:千円) |
| 前事業年度 (2023年12月31日) | 当事業年度 (2024年12月31日) |
負債の部 | | |
流動負債 | | |
買掛金 | 37,735 | 27,196 |
短期借入金 | 291,000 | 281,500 |
未払金 | 116,952 | 138,103 |
未払費用 | 25,587 | 29,557 |
未払法人税等 | 23,952 | 2,531 |
前受金 | 31,200 | - |
預り金 | 5,880 | 14,543 |
賞与引当金 | 6,730 | - |
流動負債合計 | 539,038 | 493,432 |
固定負債 | | |
資産除去債務 | 54,692 | 55,120 |
固定負債合計 | 54,692 | 55,120 |
負債合計 | 593,731 | 548,553 |
純資産の部 | | |
株主資本 | | |
資本金 | 2,388,422 | 995,525 |
資本剰余金 | | |
資本準備金 | 3,988,202 | 1,935,799 |
資本剰余金合計 | 3,988,202 | 1,935,799 |
利益剰余金 | | |
その他利益剰余金 | | |
繰越利益剰余金 | △5,236,350 | △1,020,776 |
利益剰余金合計 | △5,236,350 | △1,020,776 |
自己株式 | △292 | △292 |
株主資本合計 | 1,139,981 | 1,910,255 |
新株予約権 | 17,741 | 10,048 |
純資産合計 | 1,157,723 | 1,920,303 |
負債純資産合計 | 1,751,454 | 2,468,857 |
E2609645830株式会社カイオム・バイオサイエンスChiome Bioscience Inc.通期第2号参考様式 [日本基準](非連結)Japan GAAPfalseCTE2024-01-012024-12-31FY2024-12-312023-01-012023-12-312023-12-311falsefalsefalse458302024-01-012024-12-31jppfs_cor:NonConsolidatedMemberjppfs_cor:RetainedEarningsBroughtForwardMember458302024-12-31jppfs_cor:TreasuryStockMemberjppfs_cor:NonConsolidatedMember458302024-01-012024-12-31jppfs_cor:TreasuryStockMemberjppfs_cor:NonConsolidatedMember458302023-12-31jppfs_cor:TreasuryStockMemberjppfs_cor:NonConsolidatedMember458302023-01-012023-12-31jppfs_cor:TreasuryStockMemberjppfs_cor:NonConsolidatedMember458302022-12-31jppfs_cor:TreasuryStockMemberjppfs_cor:NonConsolidatedMember458302024-01-012024-12-31jppfs_cor:NonConsolidatedMemberjppfs_cor:SubscriptionRightsToSharesMember458302023-12-31jppfs_cor:NonConsolidatedMemberjppfs_cor:CapitalStockMember458302023-12-31jppfs_cor:LegalCapitalSurplusMemberjppfs_cor:NonConsolidatedMember458302023-12-31jppfs_cor:CapitalSurplusMemberjppfs_cor:NonConsolidatedMember458302023-12-31jppfs_cor:RetainedEarningsBroughtForwardMemberjppfs_cor:NonConsolidatedMember458302023-01-012023-12-31jppfs_cor:SubscriptionRightsToSharesMemberjppfs_cor:NonConsolidatedMember458302024-12-31jppfs_cor:ShareholdersEquityMemberjppfs_cor:NonConsolidatedMember458302024-12-31jppfs_cor:CapitalStockMemberjppfs_cor:NonConsolidatedMember458302024-12-31jppfs_cor:CapitalSurplusMemberjppfs_cor:NonConsolidatedMember458302024-12-31jppfs_cor:LegalCapitalSurplusMemberjppfs_cor:NonConsolidatedMember458302024-12-31jppfs_cor:RetainedEarningsMemberjppfs_cor:NonConsolidatedMember458302022-12-31jppfs_cor:LegalCapitalSurplusMemberjppfs_cor:NonConsolidatedMember458302024-12-31jppfs_cor:NonConsolidatedMember458302024-01-012024-12-31jppfs_cor:NonConsolidatedMember458302023-12-31jppfs_cor:NonConsolidatedMember458302023-01-012023-12-31jppfs_cor:NonConsolidatedMember458302022-12-31jppfs_cor:NonConsolidatedMember458302022-12-31jppfs_cor:CapitalStockMemberjppfs_cor:NonConsolidatedMember458302023-01-012023-12-31jppfs_cor:NonConsolidatedMemberjppfs_cor:CapitalStockMember458302023-01-012023-12-31jppfs_cor:LegalCapitalSurplusMemberjppfs_cor:NonConsolidatedMember458302023-01-012023-12-31jppfs_cor:CapitalSurplusMemberjppfs_cor:NonConsolidatedMember458302023-01-012023-12-31jppfs_cor:NonConsolidatedMemberjppfs_cor:RetainedEarningsBroughtForwardMember458302023-01-012023-12-31jppfs_cor:RetainedEarningsMemberjppfs_cor:NonConsolidatedMember458302023-01-012023-12-31jppfs_cor:ShareholdersEquityMemberjppfs_cor:NonConsolidatedMember458302023-12-31jppfs_cor:SubscriptionRightsToSharesMemberjppfs_cor:NonConsolidatedMember458302023-12-31jppfs_cor:ShareholdersEquityMemberjppfs_cor:NonConsolidatedMember458302023-12-31jppfs_cor:NonConsolidatedMemberjppfs_cor:RetainedEarningsMember458302024-12-31jppfs_cor:RetainedEarningsBroughtForwardMemberjppfs_cor:NonConsolidatedMember458302024-12-31jppfs_cor:SubscriptionRightsToSharesMemberjppfs_cor:NonConsolidatedMember458302024-01-012024-12-31jppfs_cor:ShareholdersEquityMemberjppfs_cor:NonConsolidatedMember458302024-01-012024-12-31jppfs_cor:CapitalStockMemberjppfs_cor:NonConsolidatedMember458302024-01-012024-12-31jppfs_cor:CapitalSurplusMemberjppfs_cor:NonConsolidatedMember458302024-01-012024-12-31jppfs_cor:LegalCapitalSurplusMemberjppfs_cor:NonConsolidatedMember458302024-01-012024-12-31jppfs_cor:RetainedEarningsMemberjppfs_cor:NonConsolidatedMember458302022-12-31jppfs_cor:CapitalSurplusMemberjppfs_cor:NonConsolidatedMember458302022-12-31jppfs_cor:RetainedEarningsBroughtForwardMemberjppfs_cor:NonConsolidatedMember458302022-12-31jppfs_cor:NonConsolidatedMemberjppfs_cor:RetainedEarningsMember458302022-12-31jppfs_cor:NonConsolidatedMemberjppfs_cor:ShareholdersEquityMember458302022-12-31jppfs_cor:NonConsolidatedMemberjppfs_cor:SubscriptionRightsToSharesMember458302025-02-13458302024-01-012024-12-31458302024-12-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:TotalOfReportableSegmentsAndOthersMember458302024-12-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-45830:DrugDiscoveryAndDevelopmentReportableSegmentsMember458302024-12-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-45830:DrugDiscoverySupportReportableSegmentsMember458302024-12-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:ReconcilingItemsMember458302024-01-012024-12-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:TotalOfReportableSegmentsAndOthersMember458302024-01-012024-12-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-45830:DrugDiscoveryAndDevelopmentReportableSegmentsMember458302024-01-012024-12-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-45830:DrugDiscoverySupportReportableSegmentsMember458302024-01-012024-12-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:ReconcilingItemsMember458302023-12-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:TotalOfReportableSegmentsAndOthersMember458302023-12-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-45830:DrugDiscoveryAndDevelopmentReportableSegmentsMember458302023-12-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-45830:DrugDiscoverySupportReportableSegmentsMember458302023-12-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:ReconcilingItemsMember458302023-01-012023-12-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:TotalOfReportableSegmentsAndOthersMember458302023-01-012023-12-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-45830:DrugDiscoveryAndDevelopmentReportableSegmentsMember458302023-01-012023-12-31jppfs_cor:NonConsolidatedMembertse-anedjpfr-45830:DrugDiscoverySupportReportableSegmentsMember458302023-01-012023-12-31jppfs_cor:NonConsolidatedMemberjpcrp_cor:ReconcilingItemsMember458302024-12-31jppfs_cor:NonConsolidatedMemberjppfs_cor:OtherCapitalSurplusMember458302024-01-012024-12-31jppfs_cor:NonConsolidatedMemberjppfs_cor:OtherCapitalSurplusMember458302023-12-31jppfs_cor:NonConsolidatedMemberjppfs_cor:OtherCapitalSurplusMemberiso4217:JPYxbrli:pure